A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

NCT06677307 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated for business decision reasons.

Conditions

Alpha-1 Anti-trypsin Deficiency
AATD

Interventions

DRUG: KRRO-110

Sponsor

Korro Bio, Inc.